Stifel Financial
NGM

Stifel Financial’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Stifel Financial’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17,550
Closed -$346K – 3442
2021
Q2 		$346K Buy
+17,550
New +$411K ﹤0.01% 2806

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Stifel Financial's NGM Position: Q3 2021 in Review

Stifel Financial sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2021, closing a stake of 17,550 shares — an estimated $346K sold.

Stifel Financial first reported a position in NGM in Q2 2021 and held it in 1 quarter. The position peaked at $346K in Q2 2021. 120 funds tracked by Wall St. Rank hold NGM as of Q3 2021.

  • Stifel Financial reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Stifel Financial sold 17,550 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $346K.
  • Stifel Financial first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Stifel Financial's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $346K in Q2 2021.
  • 120 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Stifel Financial's 13F filing for Q3 2021, filed 15 Nov 2021.